Compare Incyte Corporation (INCY) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Stitch Fix Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Stitch Fix Inc trades at $3.94 (market cap $520.36M). The key difference: Incyte Corporation is far larger — about 44.4× Stitch Fix Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SFIX | |
|---|---|---|
Market Cap | $23.11B | $520.36M |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $5.83 |
52-Week Low | $67.38 | $3.06 |
Enterprise Value | $19.13B | $408.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Stitch Fix (SFIX) trades at $3.84, up 1.32% today, showing signs of stabilization after a challenging period. The stock exhibits a bullish technical signal with improving fundamentals, including narrowing losses and a debt-free balance sheet. Recent quarters show earnings beats, with Q1 2026 actual EPS of -$0.01 beating expectations of -$0.06. Revenue remains stable at $1.27 billion for 2025, while net losses have decreased significantly from -$207 million in 2022 to -$28.74 million in 2025. AI-driven personalization initiatives and active client growth are key positive developments.
The outlook for SFIX is cautiously optimistic as the company's turnaround gains traction. Investment opportunities include potential upside to the $4.75 consensus price target, representing 24% upside, and continued margin improvement. Risks include persistent net losses, competitive pressures in online retail, and sensitivity to consumer spending trends. The stock's low P/S ratio of 0.39 suggests undervaluation if the recovery continues, but execution risks remain substantial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
